Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Amortization of Deferred Charges for 7 consecutive years, with $900000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Amortization of Deferred Charges rose 12.5% year-over-year to $900000.0; the trailing twelve-month figure through Jun 2026 stood at $3.5 million (up 7.44% YoY), and the FY2025 full-year result was $3.4 million, up 13.07% from the prior year.
• Amortization of Deferred Charges steadied at $900000.0 in Q2 2026 per XERS's latest filing, from $900000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $900000.0 in Q1 2026 and bottomed at $219000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $666944.4 across 5 years, with a median of $700000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges dropped 12.75% in 2022, then soared 150.23% in 2023.
• Over 5 years, Amortization of Deferred Charges stood at $489000.0 in 2022, then grew by 3.27% to $505000.0 in 2023, then jumped by 59.8% to $807000.0 in 2024, then grew by 10.66% to $893000.0 in 2025, then increased by 0.78% to $900000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $900000.0, $900000.0, and $893000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.